A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults
Authors:
- Justin R OrtizJOJustin R Ortiz
- David I BernsteinDBDavid I Bernstein
- Christopher W WoodsCWChristopher W Woods
- Micah T McClainMMMicah T McClain
- Rebecca C BradyRBRebecca C Brady
- Christopher BryantChristopher Bryant
- Ashley WegelAWAshley Wegel
- Robert W FrenckRFRobert W Frenck
- Emmanuel B WalterEWEmmanuel B Walter
- Getahun AbateGetahun Abate
Open Access
- 26 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (3) , 287-298
Abstract
We evaluated the associations between baseline influenza virus–specific hemagglutination inhibition (HAI) and microneutralization (MN) titers and subsequent symptomatic influenza virus infection in a controlled human infection study. We inoculated unvaccinated healthy adults aged 18–49 years with an influenza A/California/04/2009/H1N1pdm-like virus (NCT04044352). We collected serial safety labs, serum for HAI and MN, and nasopharyngeal swabs for reverse-transcription polymerase chain reaction (RT-PCR) testing. Analyses used the putative seroprotective titer of ≥40 for HAI and MN. The primary clinical outcome was mild-to-moderate influenza disease (MMID), defined as ≥1 postchallenge positive qualitative RT-PCR test with a qualifying symptom/clinical finding. Of 76 participants given influenza virus challenge, 54 (71.1%) experienced MMID. Clinical illness was generally very mild. MMID attack rates among participants with baseline titers ≥40 by HAI and MN were 64.9% and 67.9%, respectively, while MMID attack rates among participants with baseline titers P = .126) for every 2-fold increase in baseline HAI. There were no significant adverse events. We achieved a 71.1% attack rate of MMID. High baseline HAI and MN were associated with protection from illness. Clinical Trials Registration. NCT04044352.Keywords
All Related Versions
Funding Information
- NIAID
- National Institutes of Health
- (NIH) (HHSN272201300016I)
- Cincinnati Children's Hospital Medical Center (75N93021C00012)
- The Emmes Company (HHSN272201300022I)
- University of Maryland (HHSN2722013000017I)
- Duke University (HHSN272201300018I)
- Emory University (HHSN272200800003C)
- Saint Louis University (HHSN272201300015I)
- Baylor College of Medicine
- Institute for Clinical and Translational Research
- at the
- Baltimore
- National Center for Advancing Translational Sciences
- Clinical Translational Science Award (1UL1TR003098))
This publication has 33 references indexed in Scilit:
- Experimental human influenza: observations from studies of influenza antiviralsAntiviral Therapy, 2012
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008
- Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense.Journal of Clinical Investigation, 1998
- Cold Recombinant Influenza B/Texas/1/84 Vaccine Virus (CRB 87): Attenuation, Immunogenicity, and Efficacy against Homotypic ChallengeThe Journal of Infectious Diseases, 1990
- Cell-Mediated Immune Responses in Humans after Induced Infection with Influenza A VirusThe Journal of Infectious Diseases, 1977
- Influenza: Response of T-Cell Lymphopenia to ThymosinNew England Journal of Medicine, 1976
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972
- Experimental Infection of Human Volunteers with Equine Influenza VirusNature, 1965
- INVESTIGATION ON VOLUNTEERS INFECTED WITH THE INFLUENZA VIRUSThe American Journal of the Medical Sciences, 1937